Literature DB >> 30773944

Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer.

Yanfeng Gao1, Shuang Zhou2, Lizhi Pang3, Juechen Yang4, Han John Li5, Xiongwei Huo6, Steven Y Qian3.   

Abstract

The thunder god vine (Tripterygium wilfordii Hook. F) is traditionally used for inflammation-related diseases in traditional Chinese medicine. In recent years, celastrol (a natural compound from the root of the thunder god vine) has attracted great interest for its potential anticancer activities. The free radical nitric oxide (NO) is known to play a critical role in colorectal cancer growth by promoting tumour angiogenesis. However, how celastrol influences the NO pathway and its mechanism against colorectal cancer is largely unknown. In this study, we investigated the effects and mechanism of celastrol on nitric oxide synthase (NOS) and the angiogenesis pathway in colorectal cancer. Our data show that celastrol inhibited HT-29 and HCT116 cell proliferation, migration, and NOS activity in the cytoplasm. The antiproliferation activity of celastrol was associated with the inhibition of iNOS and eNOS in colorectal cancer cells. Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway. In addition, combinational use of celastrol with 5-fluorouracil, salinomycin, 1400 W, and L-NIO showed enhanced inhibition of colorectal cancer cell proliferation and migration. In sum, our study suggests that celastrol could suppress colorectal cancer cell growth and migration, likely through suppressing NOS activity and inhibiting the angiogenesis pathway.

Entities:  

Keywords:  Angiogenesis; celastrol; colorectal cancer; nitric oxide synthase inhibitors

Mesh:

Substances:

Year:  2019        PMID: 30773944      PMCID: PMC6715291          DOI: 10.1080/10715762.2019.1575512

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  46 in total

1.  Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation.

Authors:  Gautam Sethi; Kwang Seok Ahn; Manoj K Pandey; Bharat B Aggarwal
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 2.  Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?

Authors:  Arjan W Griffioen
Journal:  Trends Cardiovasc Med       Date:  2007-07       Impact factor: 6.677

3.  Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.

Authors:  A J Marrogi; W D Travis; J A Welsh; M A Khan; H Rahim; H Tazelaar; P Pairolero; V Trastek; J Jett; N E Caporaso; L A Liotta; C C Harris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

4.  Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.

Authors:  Giampietro Gasparini; Domenico Gattuso; Alessandro Morabito; Raffaele Longo; Francesco Torino; Roberta Sarmiento; Stefano Vitale; Teresa Gamucci; Luigi Mariani
Journal:  Oncologist       Date:  2005-10

Review 5.  Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

Authors:  Gilberto de Castro Junior; Fabio Puglisi; Evandro de Azambuja; Nagi S El Saghir; Ahmad Awada
Journal:  Crit Rev Oncol Hematol       Date:  2006-04-04       Impact factor: 6.312

6.  Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells.

Authors:  Hyo Won Jung; Yoo Sun Chung; Yoon Seong Kim; Yong-Ki Park
Journal:  Exp Mol Med       Date:  2007-12-31       Impact factor: 8.718

Review 7.  Nitric oxide signaling in colon cancer chemoprevention.

Authors:  Chinthalapally V Rao
Journal:  Mutat Res       Date:  2004-11-02       Impact factor: 2.433

8.  Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Authors:  Zhongzheng Lu; Yanli Jin; Lin Qiu; Yingrong Lai; Jingxuan Pan
Journal:  Cancer Lett       Date:  2009-10-12       Impact factor: 8.679

Review 9.  iNOS as a therapeutic target for treatment of human tumors.

Authors:  Brian Fitzpatrick; Manal Mehibel; Rachel L Cowen; Ian J Stratford
Journal:  Nitric Oxide       Date:  2008-05-13       Impact factor: 4.427

10.  Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer.

Authors:  Yao Dai; Jeffrey T DeSano; Yang Meng; Qing Ji; Mats Ljungman; Theodore S Lawrence; Liang Xu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-15       Impact factor: 7.038

View more
  13 in total

1.  Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis.

Authors:  Xihui Chen; Shiwen Wang; Li Zhang; Shuying Yuan; Tong Xu; Feng Zhu; Yanmei Zhang; Lijun Jia
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

2.  Celastrol inhibits the proliferation and angiogenesis of high glucose-induced human retinal endothelial cells.

Authors:  Jian Fang; Xiaoke Chang
Journal:  Biomed Eng Online       Date:  2021-06-30       Impact factor: 2.819

Review 3.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

Review 4.  S-Nitrosylation in Tumor Microenvironment.

Authors:  Vandana Sharma; Veani Fernando; Joshua Letson; Yashna Walia; Xunzhen Zheng; Daniel Fackelman; Saori Furuta
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

5.  Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment.

Authors:  Qingsi Wu; Jiading Wang; Yuanfang Wang; Ling Xiang; Yulu Tan; Jiaxing Feng; Zhirong Zhang; Ling Zhang
Journal:  Nano Res       Date:  2021-12-12       Impact factor: 10.269

Review 6.  Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.

Authors:  Margarita Neganova; Junqi Liu; Yulia Aleksandrova; Sergey Klochkov; Ruitai Fan
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 7.  Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery.

Authors:  Qiang Sun; Man He; Meng Zhang; Sha Zeng; Li Chen; Hui Zhao; Han Yang; Maolun Liu; Shan Ren; Haibo Xu
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 8.  Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications.

Authors:  Pushkaraj Rajendra Wagh; Preshita Desai; Sunil Prabhu; Jeffrey Wang
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

9.  Celastrol Alleviates Gamma Irradiation-Induced Damage by Modulating Diverse Inflammatory Mediators.

Authors:  Hong Wang; Kwang Seok Ahn; Sulaiman Ali Alharbi; Omar Hm Shair; Frank Arfuso; Gautam Sethi; Arunachalam Chinnathambi; Feng Ru Tang
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

10.  The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells.

Authors:  Lijun Wang; Luqun Tang; Chengyun Yao; Chunyan Liu; Yongqian Shu
Journal:  J Immunol Res       Date:  2021-07-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.